season strong biotech see limit
controversi quarter see best posit
risk see launch stori
gwph key focu stock investor
ow pt ep mse
revenu vs con driven mainli conservat sensipar
recal multipl gener launch sensipar like
flood channel drug despit long-term settlement keep
gener market thu assum continu sensipar inventori
drawdown assum price pressur neulasta aranesp
posit inventori swing greater net price recoveri factor
could lead upsid question quarter includ management focu area
busi develop updat net price aimovig praulent
bearish investor believ recov low management
comment current polit environ potenti legisl impact
drug price miss could alarm investor given
typic season strong believ could face pressur
quarter
uw pt ep mse overal view
estim broadli in-line consensu total revenu
lower ep like driven view cost vs consensu question
quarter includ near-term commentari around impact
spinraza zolgensma launch time updat
gi compar studi well potenti market impact new
competit ms oral particular multipl new oral launch year
novarti data view price market share impact key
management view key pipelin readout includ psp expect
limit volatil quarter upsid bia given typic
season around posit gross-to-net inventori trend would expect
trade higher clean quarter
ew pt ep mse total
revenu vs con driven higher hiv revenu vs
con mainli biktarvi vs con ep benefit
lower spend new management could acceler spend given new ceo
day highlight need filgotinib prepared recal ranexa
letairi start face gener competit headwind
question quarter includ new ceo day meet
investor addit insight will offer reshap management
team busi import expect full strateg review
sometim fall potenti impact hiv busi
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
drug price legisl current discuss impact hiv
price market share recent gsk launch expect beat
reward drive higher
ew pt us eylea mse
rel in-line quarter investor remain focus cost trend
busi management abil manag cost sanofi jv see
biggest investor focu potenti impact upcom drug
price chang could disproportion impact eylea question
quarter includ timelin potenti impact novarti launch
brolucizumab dupix asthma launch outlook growth new
indic updat view key pipelin driver ngf
pt expect limit movement
quarter updat includ ultomiri convers alexion pipelin
progress reimburs negoti vertex hemophilia file
achondroplasia time
face volatil quarter given high
investor focu launch trajectori key product
slightli consensu vs con believ sentiment neg
thu see relief ralli in-line better sale slightli
ahead vs con see recoveri net price good script
volum commentari potenti forteo gener key
limit visibl andexxa progress estimate in-line con
believ investor mute expect versu said
order drive higher management offer clear beat view
ahead ingrezza sale vs con believ investor
view bar recal compani report record new patient
start good increas prior record tradit
higher sequenti growth quarter compani believ
clean read neurocrin continu benefit recent sale
forc expans new hire catch legaci team ultragenyx
slightli crysvita sale vs con would watch
indic crysvita launch benefit improv access
genet test pedigre analysi although focu remain
main near-term catalyst
cabometyx sale vs con would expect increas
cabometyx wholesal inventori sinc low end histor
rang end
ow pt gwph ow pt alnylam expect
onpattro continu strong launch trajectori potenti exceed
estim approv vyndaqel attr-cm creat
headwind stock believ unlik impact sale
label drug overlap believ
highli like epidiolex exceed estim management care
set conserv expect despit larg increas
ftsv ow pt lower pt base sole expect higher
dilut equiti rais continu believ management clear path
acceler approv expect clariti file timelin drive ftsv higher
dbvt ew pt increas pt increas base
modif near-term spend revenu
umrx ow pt lower pt base modest long term
forecast therapi liquid tumor continu see biggest potenti
upsid driver come initi work solid tumor initi data due
ow pt lower pt spend forecast
adjust slightli assum lower potenti sale indic
outsid oa continu believ initi oa data support continu
develop believ take longer convinc investor correl
platform clinic benefit therefor see less near-term upsid
pt deriv dcf use
discount rate assum po rs md transfusion-
depend beta-th addit assum po
first line md non-transfusion-depend beta-th mf
posit data mf non-transfus depend beta-th bull case
assum higher probabl success po non-transfus
depend beta-th mf
luspatercept launch reach peak ww revenu
first two indic base case assumpt describ price
target methodolog
luspatercept launch slower-than-expect bear case assum peak
us market share md beta-th respect
addit assum luspatercept success follow-on indic
equal-weight rate base
expect limit upsid near-term
posit luspatercept
assum high probabl approv
next set data
luspatercept phase data beta-th
top-line luspatercept phase data mf
preliminari phase part data
preliminari phase part data
data non-transfus depend beta-th
preliminari sotatercept data phase
pulsar studi patient pah
risk achiev price
upsid risk better-than-expect mf
downsid risk neg mf fshd data
vadadustat drive akebia share
vadadustat drive akebia share
pt deriv dcf use discount rate
termin growth rate beyond valu akebia nephrolog
vadadustat exce expect allow therapi take addit share
epo regimen appli risk adjust
vadadustat launch drug profil allow success howev
ampl risk remain program lead risk adjust
vadadustat fail merger fall compani valu cash
equal-weight ahead phiii
major cardiac event mace data
see vadadustat therapi
benefit allow remov black
box respect cardiovascular event
might necessari success versu
roxadustat lead time roxadustat
unabl establish mace non-inferior
dd ndd select
achiev mace read-through
vadadustat mix expect share
face pressur remain
infrastructur auryxia need show us
recent merger keryx
auryxia join vadadustat compani
ckd aresen auryxia
underperform sinc approv
hypophosphatemia though drug
recent expand label includ iron
defici anemia need see
drug perform gain confid
potenti expect updat model
keryx merger earn
main valuat driver
perceiv clinic regulatori risk
vadadustat ckd dialysi set
risk achiev price
vadadustat demonstr lack efficaci
signific safeti issu emerg lead
program discontinu
roxadustat compet ckd
akebia might need rais addit fund
issu equiti
pt deriv dcf use
discount rate given posit phase data assum
probabl success po howev fourth cgrp
market assum peak market share episod migrain
chronic migrain impli peak unadjust sale
stronger uptak follow success cgrp bull case assum
greater adopt peak market share episod migrain
eptinezumab approv base case assumpt describ
price target methodolog
eptinezumab fail bear case alder unabl obtain approv
eptinezumab aldr trade cash value-per-share
underweight thesi base
eptinezumab like fourth cgrp
although eptinezumab fast onset
action view efficaci cgrp
howev eptinezumab less conveni
administ iv infus cgrp
inject subcutan addit
least one oral cgrp could approv
episod migrain within coupl year
believ physician prescrib
eptinezumab sever patient
risk achiev price
risk upsid alder announc
new product candid rel
advanc indic larg market
approv addit cgrp
better-than-expect sale eptinezumab
risk downsid launch
cgrp significantli street
expect new safeti signal
detect cgrp believ
class effect
safeti efficaci data ftd-grn drive risk/reward
safeti efficaci data ftd-grn
pt deriv dcf use discount
rate termin growth rate revenu driver model
current model
separ given earli stage develop
commerci strong uptak bull
case valu product launch
begin respect gener
sale
success commerci base
case valu product launch
begin respect gener
risk-adjust sale
fail unabl commerci trade cash
overweight thesi base
success commerci
design treat well defin
genet diseas measur biomark
compar neurodegen
probabl success
phi trial healthi volunt
demonstr target engag
provid confid impact genet
target defin receptor
implic alzheim diseas risk
share partner limit
financi risk sharehold
phib data ftd-pgrn
demonstr safeti efficaci expect
phii data ftd-pgrn patient also
demonstr clinic activ expect
demonstr efficaci
alzheim diseas expect
risk achiev price
signal would like caus investor
question valu
reduc efficaci ftd
delay timelin posit data
competitor could weigh
market share especi competitor data
arriv new indic prior pivot
effect treat
sale
research develop
gener administr
net loss comprehens loss
cash equival
receiv collabor partner
prepaid expens current asset
properti equip net
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
chang oper asset liabil
accret discount market secur
loss dispos market secur
prepaid expens current asset
accru liabil accru clinic suppli cost
net cash use oper activ
purchas properti equip
purchas market secur
matur market secur
net cash use invest activ
payment convert prefer stock issuanc cost
proce issuanc common stock
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
ultomiri share convers soliris/strensiq/kanuma sale growth drive
ultomiri share convers soliris/strensiq/kanuma sale growth drive
overweight believ
current valuat impli manag
unabl grow busi
overlook share shift potenti
ultomiri even conserv scenario
assum ultomiri achiev solid
profil assum either market share
price pressur year
assum strensiq achiev
meaning sale see modest sale
key revenu driver model
continu ahu pnh sale growth
franchis coupl growth
soliri mg success share shift
ultomiri model nmo sale start
risk achiev price
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur
share convers soliri ultomiri
project
could potenti bad
behavior identifi commerci
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu
driver model pnh sale ahu sale mg sale nmo sale
strensiq sale kanuma sale incorpor cash cost
diagnost algorithm drive sustain pnh ahu mg penetr
ultomiri succe signific share convers bull case assum
soliri becom standard care pnh ahu nmo mg pnh
sale peak ww ahu sale
peak assum strensiq kanuma continu launch sale
respect
soliri meaning growth pnh ahu gmg ultomiri succe
modest share convers base case assum solid convers ultomiri
long-term durabl complement franchis assum gmg
nmo meaning contribut sale also assum strensiq peak sale
kanuma see soliri longev incorpor
competit price pressur
soliri face signific competit strensiq kanuma achiev minim
sale bear case assum soliri fail gain label expans soliri
face signific headwind biosimilar proprietari competit
diversif strensiq kanuma minim
provis incom tax
million
equival
prepaid expens current
properti equip net
goodwil intang
defer financ asset
current portion long-term debt
current portion conting consider
accumul comprehens incom
total liabil sharehold equiti
million
impari fix assets/chang fair valu
impair intang asset
sale secur
compens expens relat stock option
stock option expens net tax benefit
non-cash expens acquir ipr
chang asset liabil
chang inventori
chang a/r
mileston receiv reimbus contract cost
prepaid expens
net cash provid use oper activ
purchas market secur
sales/matur market secur
purchas ppe
invest patents/licens tech acquisit
purchas invest
net cash use invest activ
proce issuanc common stock
proce revolv credit facil
proce exercis stock option
tax benefit exercis stock option
issuanc debt
repay debt
issuanc repay credit facil
equiti issuanc cost share issu connect
acquisit busi
repurchas stock
payment conting consider
net cash provid financ activ
effect exchang rate chang cash equival
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
onpattro sale advanc pipelin drive valu
onpattro sale advanc pipelin drive valu
pt deriv dcf use discount rate
termin growth rate beyond valu alnylam advanc
attr platform highli success givosiran lumasiran achiev strong sale
fitusiran inclisiran launch bull scenario assum onpattro
follow-on highli success form attr
givosiran lumasiran launch sell well fitusiran inclisiran
abl success gain approv appli modest pipelin valu
drug includ inclisiran cemdisiran
attr franchis drive valu givosiran launch lumasiran launch
onpattro strong launch attr la launch aln-
drive sale model aip revenu givosiran
begin howev risk adjust lumasiran launch
risk adjust appli modest pipelin valu drug
onpattro launch modest sale givosiran launch
onpattro achiev modest sale givosiran launch
overweight alnylam
believ mani risk challeng
alnylam give way
commerci growth expect
investor focu onpattro launch
exceed expect view
expect givosiran launch
lumasiran
view alnylam rnai platform
high potenti valu consid
rnai simpler demonstr
preclin proof concept
technolog alnylam larg pipelin
beyond ttr therapi offer potenti
substanti downstream valu
ramp onpattro well
clinical/regulatori updat
givosiran lumasiran fitusiran inclisiran
drive share
risk achiev price
pipelin failur proprietari
rnai therapi could lead substanti
chang share valu
neg safeti and/or efficaci data
therapeut program
clinic data competit program
suggest disadvantag drug
biosimilar competit pipelin contribut drive risk-reward
biosimilar competit
overweight amgen believ
upsid pipelin recent
launch help reduc long-term risk
compani current base busi face
signific in-organ opportun growth
stabl base even biosimilar
believ protect key franchis
biosimilar competit near-term
long-term forecast gradual share
shift biosimilar versu cliff key
product neulasta enbrel
project period
divers pipelin begin
appreci gener posit
late-stag data key pipelin compound
earli aimovig launch migrain
appear encourag also
develop portfolio biosimilar
molecul believ take share
also watch matur
certain early-stag oncolog program
shown progress recent month
launch perform aimovig
erenumab migrain approv launch
biosimilar molecul
advanc early-stag
biosimilar entrant key legaci product
enbrel neulasta enbrel price power
risk achiev price
failur late-stag pipelin
lack margin expans
deriv pt discount cash flow dcf analysi
use wacc termin growth rate post
bear case main revenu driver model
eros base busi due biosimilar matur
lower biosimilar impact coupl outsiz revenu pipelin
assum pipelin sale even biosimilar
repatha sale modest line penetr kyproli
sale enbrel long-term patent hold
biosimliar enter market minim impact biosimilar
expos product biosimilar neulasta take total neulasta share
us biosimilar impact similar trend europ modest result
pipelin assum pipelin sale even
biosimilar repatha sale line
penetr kyproli relapsed/refractori market global
sale enbrel biosimilar begin take share
modest impact biosimilar expos product biosimilar neulasta take
total neulasta share
repatha sale line penetr kyproli
relapsed/refractori market sale enbrel biosimilar enter
market take signific share brand enbrel notabl
impact biosimilar expos product biosimilar neulasta take
total neulasta share assum sg save lt
sg sale
safeti efficaci data mg itp pv drive risk/reward
safeti efficaci data mg itp pv
pt deriv dcf use
discount rate termin growth rate revenu driver
model
commerci strong uptak bull case
valu risk adjust vari
product launch begin
respect gener sale
argenx success commerci base
case valu mg itp pv aml ctcl risk adjust vari
product launch begin
respect gener sale
fail argenx unabl commerci argx trade
overweight thesi base
success commerci
sever compani develop anti-
fcrn antibodi treatment
autoimmun diseas mani compani
report safeti and/or reduc efficaci
compar
design uniqu ph-
depend bind profil extend
therapeut durabl fewer report
advers event compar compet anti-
diseas indic demonstr
efficaci safeti
demonstr clinic
activ aml
phiii data gmg demonstr
differenti safeti efficaci
phii data pv itp also
top-line phiii data gmg expect
demonstr efficaci aml
risk achiev price
signal would like caus investor
question differenti valu
reduc efficaci
delay timelin posit data
competitor could weight
market share especi competitor data
arriv new indic prior pivot
effect treat
refractori aml patient compar
standard care
euro million
sale
research develop
sell gener administr
oper expens
euro million
cash equival
research develop incent receiv
trade receiv
research develop incent receiv
properti equip net
trade payabl
provis employe benefit
total liabil stockhold equiti
euro million
adjust reconcil net loss net cash use oper activ
depreci properti plant equip
amort intang asset
loss dispos fix asset
provis employe benefit
expens recogn respect sharebas payment
chang oper asset liabil
trade receiv
trade payabl
net cash use oper activ
purchas properti equip
purchas intang asset
increas /decreas current financi asset
net cash use invest activ
proce issu share
transact cost equiti issu
net cash provid financ activ
net increas decreas cash cash equival
exchang gains/ loss cash cash equival
cash equival begin period
cash equival end period
attract lentivir gene therapi platform drive valu
attract lentivir gene therapi platform drive valu
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model risk adjust sale fabri diseas gaucher
diseas market well underli gene therapi platform valu
steeper ramp fabri gaucher scenario assum first revenu avr-rd-
reach peak appli risk adjust
launch reach peak risk
adjust includ modest peak adjust sale pomp cystinosi
fabri gaucher drive valu scenario assum first revenu
reach peak appli risk adjust avr-
launch reach peak risk
program fail valu cash
gene therapi compani
develop lentivir therapi lysosom
compani lead therapi
fabri diseas alreadi clinic data
human suggest therapi
could potenti cur derisk
establish market alreadi identifi
popul also regulatori path well
establish make diseas less riski
rare diseas opportun
program earliest
potenti approv primari driver
valuat gaucher
diseas also key driver
risk achiev price
poor clinic data neg impact
street view specif pipelin
product gene therapi whole would
detriment share valu
lsd establish market
standard care product
like higher bar success
compet technolog gene
competit risk long haul
success develop i/o combin therapi access ex-china market
success develop i/o combin therapi access ex-china market
execut local china market drive risk/reward
execut local china market drive risk/reward
overweight beigen preclin
earli clinic data indic beigen four
parp inhibitor could
present differenti profil varieti
beigen uniqu posit develop
i/o combin therapi given own
compon drug preclin studi in-
hous combin promis date
choos develop drug china
beigen elig pursu potenti
acceler path approv
multi-national competitor could provid
year head start access chines
uptak oncolog drug china
indic strong demand healthcar
insur reform grow market
time believ chines market
could serv valuat backstop
beigen deal celgen provid
commerci portfolio china provid
infrastructur help facilit eventu
commerci beigen product
candid china
updat chines penetr
btk parp program
monotherapi combin platform
updat pathway
risk achiev price
on-going clinic trial particularli
inabl demonstr superior
compet compound later-stag
develop market
regulatori chang china
develop posit access
pt deriv dcf use discount rate
termin growth rate beyond valu beigen four clinic
stage product candid recent acquir oper china
beigen four product candid achiev strong uptak china
ex-china market driven differenti profil uniqu
combin therapi product sale reach
beigen
earn royalti ex-china
sale respect revlimid abraxan vidaza china gener
annual sale beigen earn aggreg
develop regulatori commerci mileston payment
collabor celgen
beigen abl launch four current clinic stage product
candid modest uptak within outsid china product sale
estim
beigen earn
royalti ex-china sale respect
revlimid abraxan vidaza china gener annual sale
beigen earn aggreg develop regulatori
commerci mileston payment collabor
failur develop launch molecul combin therapi china
spinraza tecfidera ocrevu pipelin drive risk-reward
spinraza tecfidera ocrevu pipelin drive risk-reward
ocrevu pipelin
tecfidera reach higher market share limit impact biosimilar
signific margin expans lower discount pipelin asset
assum peak tecfidera sale gener limit
declin plegridy/avonex franchis continu
tysabri growth peak sale flatten spinraza sale
limit impact rituxan/gazyva biosimilar
impact assum peak tecfidera sale gener
enter declin plegridy/avonex sale
stabl tysabri sale biosimilar rituxan impact start
mainli off-set grow ocrevu royalti
impact pipelin assum global tecfidera sale
loss patent protect declin plegridy/avonex sale
greater competit signific neg price
environ biosimilar rituxan impact start
uw rate base view
risk base busi weigh
spinraza competit potenti
rituxan biosimilar overhang
tecfidera ipr expect
management track record transform
late-stag limit
expect signific capit
management chang strategi
risk achiev price
faster expect launch new
amort acquir intang asset
acquir in-process research develop
tecfidera litig settlement licens charg
loss sale right
total incom loss
net incom non-controlling interest
net incom non-gaap
oper expens
us record
fampyra eu
rituxan gazyva profit share
revenu collabor relationship
royalti corpor revenu
equival
due unconsolid joint busi
invest asset
current portion debt line credit
accru expens
note payabl financ
accumul comprehens incom
chang oper asset liabil
accru expens current liabil
liabil tax payabl
conting consider relat fumapharm ag acquisit
purchas treasuri stock
proce issuanc stock stock comp
excess tax benefit share-bas compens
proce issuanc long-term debt
net distribut non-controlling interest
effect exchang rate chang
rimegep competitor migrain data glutam platform valid drive
rimegep competitor migrain data glutam platform valid drive
deriv pt discount cash flow dcf analysi
assum wacc termin growth rate post
main revenu driver model rimegep
episod migrain lesser extent glutam platform
robust rimegep uptak episod migrain commerci
chronic migrain strong share addit neurolog indic
glutam platform net product sale driven
sale rimegep aggreg cgrp
platform ex-u sale aggreg sale trigriluzol bhv-
 ex-u
strong share rimegep episod migrain modest share
addit neurolog indic glutam platform
net product sale driven sale rimegep
ex-u commerci commerci
chronic migrain aggreg sale trigriluzol bhv-
 commerci ex-u
pipelin failur rimegep glutam platform molecul fail
develop process compani trade cash value-per-share
equal-weight biohaven lead
larg unmet need acut treatment
migrain phiii data suggest product
could differenti emerg
competitor particularli safeti howev
believ valuat reflect posit
aspect thu see balanc
signific pipelin driver troriluzol bhv-
gener encourag
data troriluzol achiev
statist signific result phii/iii
spinocerebellar ataxia sca program
result drug inabl differenti
placebo seem trial/ind specif
current see limit read
glutam program expect key
data glutam platform
rimegep file
commerci clariti
glutam data particularli troriluzol
risk achiev price
regulatori hurdl rimegep
poor safety/efficaci data
sale
mileston payment licensor
research develop
gener administr
provis incom tax
net loss comprehens loss
net incom loss attribut non-control interest
non-control interest net incom
st invest
cash equival
prepaid expens current asset
properti equip net
note payabl net discount
note payabl relat parti
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
benefit defer incom tax
fair valu conting equiti liabil licens agreement
issuanc common share consider licens agreement
fair valu warrant issu consider licens agreement
chang fair valu warrant liabil
chang fair valu deriv liabil
chang fair valu conting equiti liabil
loss equiti method invest
chang oper asset liabil
prepaid expens current asset
net cash use oper activ
purchas properti equip
purchas equiti method invest
increas restrict cash
net cash use invest activ
proce issuanc seri convert prefer share
proce issuanc common share
payment offer cost
proce issuanc note payabl
payment debt issuanc cost
collect note receiv sharehold
advanc payment receiv second close seri convert prefer share
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
base busi brineura vosoritid bmn drive valu
base busi brineura vosoritid bmn drive valu
aldurazym pipelin vosoritid bmn greatest
extra strength pipelin assum expect growth base
busi drug pipelin vosoritid bmn becom even larger
driver valu
pipelin contribut assum base busi perform well come
year also pegvalias approv trifecta vosoritid bmn
 bmn launch model probabl success
vosoritid bmn bmn
pipelin current approv drug assum drug
pipelin unabl gener satisfactori result gain market approv
bear scenario
leader orphan opportun biomarin
uniqu player core
compet orphan drug set apart
larg cap emphas market
target larger popul
strength base busi establish
valu base busi vimizin naglazym
kuvan aldurzym contribut
revenu given natur market outsid
competit unlik allow base
busi creat valuat backstop
deep pipelin offer plenti
opportun upsid biomarin deep
wide product pipelin multipl drug
potenti launch end
vosoritid bmn possibl
blockbust contribut upsid
pipelin opportun near-term focu
investor focu pipelin
opportun nearer-term launch
pegvalias pku well potenti
blockbust vosoritid achondroplasia
bmn gene therapi treatment
find patient drive sale
base busi base busi drug
still grow recent launch
vimizim still leg drive sale
biomarin abil steadili find new patient
grow revenu opportun
bmn hemophilia gene therapi
bmn could signific impact
valuat matur data becom
risk achiev price
neg updat key pipelin drug
highlight safeti efficaci risk
bmn failur phase
focu orphan asset price could
impact investor view base busi
pipelin upsid particularli impact
termin valu busi
expens manag particular
meet year oper margin target
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
signific sickl cell uptak bcma car-t high share relaps set
modest beta-thalassemia penetr assum larg portion
elig scd patient receiv gene therapi signific portion
new incid popul receiv therapi beta-thalassemia assum
row penetr assum strong launch penetr
front line patient
uptak beta-thalassemia us/eu strong bcma car-t uptak
line moder sickl cell penetr scd project peak ww sale
assum oral competit baselin factor organ damag
stroke etc may limit uptak gene therapi beta-thalassemia
assum penetr develop market scd price
factor late line us patient drive
peak sale
lentiglobin fail make market assum scd
beta thal make market model cash-bas valu assum
launch
equal-weight
compani progress sickl cell diseas
reflect valuat see car-t
bcma program main upsid
believ initi data repres
proof-of-concept allow us valu
penetr sickl cell market
penetr beta-thalassemia
see initi bcma car-t data
strong highli valu segment
peak sale assum
maintain major share
competit compani
addit car-t data durabl
data earlier line therapi
addit data follow-up
lentiglobin beta-th scd studi
new clinic program either gene
therapi car-t gene edit
risk achiev price
potenti efficaci safeti concern
would inhibit manag team
bring market addit
indic earlier line
efficaci lentiglobin given
limit number patient potenti
variabl patient engraft diseas
sever patient respons
safeti lentiglobin given lack
long-term follow-up limit patient
research licens fee
cost expens
sale
research develop
gener administr
licens revenu
chang fair valu conting consider
st invest
cash equival
prepaid expens current asset
properti equip net
non-curr asset restrict cash
accru expens current liabil
defer rent net current portion
conting consider net current portion
accumul comprehens incom loss
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
non-cash benefit releas incom tax valuat allow
depreci amort
remeasur conting consider
issuanc restrict common stock exchang consult servic non-employe
re-measur warrant
loss dispos equip
chang oper asset liabil
prepaid expens asset
accru expens liabil
net cash use oper activ
purchas properti equip
payment made tenant improv capit leas
purchas market secur
proce sale matur market secur
acquisit busi
net cash use invest activ
proce public offer common stock
proce issuanc convert prefer stock
repay nonrecours note collater restrict stock-
reimburs tenant improv capit leas
proce exercis stock option issuanc common stock
paid conting purchas price consider
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
chang cash due restat
cash equival begin period
cash equival end period
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model avapritinib
deeper penetr avapritinib assum deeper penetr avapritinib
line therapi kit driven gist form sm well higher
expect
avapritinib launch assum avapritinib launch pdgfr
resist gist kit gist kit driven gist project
launch appli risk
assum avapritinib use pdgfr resist gist popul
avapritinib indic unapprov
avapritinib key valu driver
blueprint drug like approv
pdgfra exon mutant gist fourth-
line gist earli gist
potenti earli data system
repres
underappreci opportun
diseas rel treatment
option current avail drug
fairli ineffect poorli toler
blueprint present earli dose rang
data show promis efficaci
appear promis though
competit dynam ret-
inhibitor could well impact
show tki highli
primari driver blueprint
avapritinib kit pdgfr mutant gist
well sm
risk achiev price
clinic failur avapritinib
due lack efficaci emerg
earlier stage pipelin fail advanc
collabor yield viabl
omecamtiv mecarbil reldesemtiv drive risk/reward
omecamtiv mecarbil reldesemtiv drive risk/reward
pt deriv dcf use
sale adjust revenu use probabl
success po om reldesemtiv al
reldesemtiv sma
greater market share bull case assum greater market peak
share omecamtiv mecarbil reldesemtiv
om reldesemtiv commerci begin base case
assumpt describ price target methodolog
product candid fail unabl advanc product
candid trade cash value-per-share
equal-weight thesi base
omecamtiv mecarbil driver
valuat de-risk phase data
expect
cautiou reldesemtiv sma
given phase data sma
despit potenti upsid al
uncertainti whether dose high
phase data
efficaci hf
omecamtiv mecarbil phase data hf
risk achiev price
data
galactic-hf continu past
interim futil analysi efficaci
step viaskin peanut program drive risk/reward
step viaskin peanut program drive risk/reward
deriv pt dcf base forecast dbv peanut
rate termin growth rate
modest share viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener peak ww sale
viaskin milk viaskin egg launch
respect obtain minim share achiev global
sale
modest uptak viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener
global sale contribut viaskin milk viaskin egg
given current regulatori issu viaskin peanut assum
probabl success
regulatori failur viaskin peanut commerci viaskin milk
and/or viaskin egg share trade cash value-per-share
equal-weight
gener mix phiii top line profil
management recent pull back bla viaskin
peanut follow issu highlight
fda management expect resubmit
bla viaskin peanut fda
believ repres next key
catalyst dbvt
viaskin milk viaskin egg repres
potenti upsid driver target
market high unmet need howev
given earli natur program
mix late-stag result viaskin peanut
egg milk program factor
bull case modest uptak
resubmiss viaskin peanut bla
risk achiev price
longer expect delay
regulatori progress viaskin peanut
greater expect competit
program al alzheim parkinson bbb platform drive risk/reward
program al alzheim parkinson bbb platform drive risk/reward
pt base dcf base case forecast
parkinson al alzheim bbb platform
discount rate assum termin growth cash
greater alzheim market share success idiopath parkinson
bull case assum market share al market share
alzheim share total parkinson popul alzheim
risk-adjust us peak sale program
program
risk-adjust success alzheim good probabl success
mutat valu bbb program base case assum
market share al market share alzheim share
mutat parkinson us peak risk-adjust sale
program program bbb program repres
total peak revenu
alzheim success mutat parkinson valu bbb
program approv al alzheim approv
parkinson al program gener peak revenu
program gener peak revenu bbb program repres
peak revenu
overweight thesi base
confid manag abil
inflect product histor
difficult treat area neurosci
believ manag right
process inflect success use
genet target biomark target
engag parallel invest
improv success initi target
repres initi yardstick
opportun greatli expand treatment
engag inhibitor
engag data patient
program
potenti evid activ idiopath
initi preclin clinic data
demonstr util bbb
risk achiev price
preclin clinic safeti signal
program
inabl advanc
program clinic test due poor
efficaci concern safeti signal
failur bbb program greater
success competitor similar program
cost expens
sale
research develop
net incom loss comprehens loss
net unreal loss market secur
st invest
cash equival
prepaid expens current asset
properti equip net
accumul comprehens incom loss
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
net amort premium discount market secur
loss dispos fix asset
fair valu common stock issu connect asset alloc
chang oper asset liabil
prepaid expens asset
accru current liabil
net cash use oper activ
purchas market secur
purchas properti equip
purchas invest
matur sale market secur
net cash use invest activ
payment issuanc cost relat common
payment issuanc cost relat prefer
issuanc common takeda collabor
proce convert promissori note receiv relat
proce exercis common stock option
proce issuanc common stock
proce issuanc convert prefer stock net
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
demonstr safe administr human ip resolut success
demonstr safe administr human ip resolut success
pt deriv dcf use discount rate
edita abl develop commerci therapi receiv widespread
uptak therapi launch us eu treat
cure address popul command premium
price gener peak ww sale edita also abl
realiz sale addit therapi car-t applic
non-malign hematolog dmd cf
therapi prove success addit therapi obtain modest
success therapi launch us eu treat
cure address popul gener peak ww
sale edita abl develop success therapi car-
hematolog dmd cf achiev sale
pipelin program fail edita abl commerci therapi
result valuat cash share
equal-weight
crispr gene edit platform
derisk oper standpoint
gear toward numer diseas
target howev deliveri long-term
safeti administ clinic relev
dose human need proven
edita system modular approach
may allow differenti
first diseas target
inherit retin dystrophi lower initi
risk prove gene edit work
human eye immun privileg
provid small contain area
suffici quantiti vector
overal see signific long-term
potenti edita remain equal-weight
initi therapi derisk clinic
progress program
program clinic
hematolog diseas genet diseas
lung liver
risk achiev price
ip outcom limit edita freedom
develop risk associ earli
natur pipelin timelin long
competitor could influenc investor
percept stock
cost expens
sale
research develop
gener administr
net incom loss prefer stock adjust
convert prefer stock prefer convert extinguish
non- adjust
research develop
gener administr
adjust numer ep
st invest
cash equival
properti equip net
equip loan current portion net discount
defer rent net current portion
equip loan net current portion discount
construct financ leas oblig net current portion
accumul comprehens incom
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
non-cash research develop expens
non-cash loss debt extinguish
chang fair valu warrant liabil
interest relat facil leas oblig
chang fair valu prefer stock tranch asset liabil
chang fair valu anti-dilut protect liabil
chang defer rent
chang oper asset liabil
up-front payment collabor
increas defer revenu
net cash use oper activ
purchas properti plant equip
proce sale fo equip
increas restrict cash
net cash use invest activ
proce equip loan net issuanc cost
proce issuanc redeem convert prefer stock tranch right net issuanc cost
payment equip loan princip
proce issuanc common stock restrict stock
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
chang due restat
cash equival begin period
cash equival end period
tazemetostat promis therapi
potenti broad applic although
see tazemetostat intrigu
approv asset potenti broad
applic size opportun
remain outstand question es small
indic like provid drug
first fda approv fl much larger
indic howev data point
later line diseas ultim look see
data demonstr efficaci earlier line
maintain ew rate
pt deriv dcf use discount rate
termin growth rate beyond valu tazemetostat
primari driver
tazemetostat treatment fl
tazemetostat approv ramp well assum tazemetostat launch es
fl dlbcl appli risk adjust
dlbcl
tazemetostat launch strength later line assum tazemetostat
launch es fl dlbcl appli risk
adjust fl dlbcl respect
risk achiev price
safeti issu emerg prevent
develop tazemetostat
might suffici efficaci
compet current treatment
collabor fail result meaning
program fail compani valu cash
probabl success monoclon microbi therapi drive risk/reward
probabl success monoclon microbi therapi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model evelo lead monoclon microbi product candid
atop dermat psoriasi
signific share atop dermat psoriasi evelo inflamm
focus monoclon microbi launch atop dermat
psoriasi atop dermat evelo product gain share peak
patient control topic treatment psoriasi evelo obtain
share peak patient biolog oral respect assum
probabl success po estim peak po adjust revenu
modest share atop dermat psoriasi evelo product candid gain
share peak atop dermat patient control
topic treatment gain share peak psoriasi
patient biolog oral respect assum po estim
peak po adjust revenu
program fail valu compani cash
treat system condit via gut-
bodi network nascent field evelo
signific clinic literatur recent
year support premis gut-bodi
network preclin data gener
date evelo lead product candid
inflamm oncolog encourag
scalabl sever potenti target
therapeut inher safe
deriv gut
initi clinic data
psoriasi atop dermat
respect
multipl oncolog studi
begin
risk achiev price
earli setback microbiom
focus compani may weigh investor
safeti efficaci lead develop
program remain unclear
therefor risk initi clinic readout
investor may write entir evelo
platform earli data readout
pt deriv dcf use discount
rate model peak us market share translat
peak sale rcc assum peak us market share
translat peak sale
greater peak market share rcc bull case assum
peak us market share translat peak sale
addit assum peak us market share rcc share
translat peak sale rcc
expect gradual launch base case assumpt
describ price target methodolog
lower long-term market share rcc greater-than-expect
competit pressur beyond cabozantinib market share declin
patent expir rcc reach share rcc
equal-weight believ
posit expect cabozantinib
rcc larg price share
limit downsid risk ahead
believ sale growth
gradual
phase data rcc
risk achiev price
cabozantinib earlier stage trial
posit expect new later
stage asset program announc
addit data report support
advanc cabozantinib indic
beyond rcc
slowli expect combin
studi cabozantinib earlier stage
trial succeed
updat antibodi drive risk/reward
updat antibodi drive risk/reward
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid dlbcl ovarian cancer colorect
cancer risk-adjust basi
strong uptak dlbcl solid tumor see strong uptak
use broadli across r/r front line dlbcl set
base case gener peak risk-adjust sale also
gain greater share colorect cancer ovarian cancer gener peak risk-
adjust sale
modest uptak dlbcl solid tumor dlbcl gener
risk-adjust revenu
assign po probabl success dlbcl gener
risk-adjust solid tumor revenu colorect cancer ovarian cancer
assign po solid tumor
fail liquid solid tumor fail develop stage
across indic result forti seven trade cash value-per-share
overweight forti seven
believ earli clinic data gener
antibodi highli encourag across
oncolog indic could first-in-
class therapi new categori checkpoint
data gener date indic
potenti strong singl agent activ
well activ could complementari
anti-canc agent
progress toward us pivot studi
upcom potenti registr studi
md aml detail come
phi data studi avelumab
ovarian cancer
phi data studi cetuximab
colorect cancer
risk achiev price
poor efficaci and/or safeti data lead
stronger expect data
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
less rapid eros hcv franchis strong pipelin realiz drive bull
case hiv product revenu reach hcv busi gener
sale ww sale yescarta filgotinib
gilead respect
rapid hcv eros lower pipelin success bull case hiv
product revenu reach hcv busi declin sale
ww sale yescarta filgotinib
gilead respect
stabl hiv revenu quick hcv busi eros minim pipelin
success hiv product revenu hcv busi gener
sale littl pipelin valu
equal-weight gilead believ
offer signific absolut
upsid near-term catalyst
term upsid rel gilead
signific return capit share
repurchas low forward price-to-earnings multipl
offer downsid protect
believ hcv peak us
continu declin modestli
howev believ cash flow gener
robust
hiv gilead done good job
switch nave patient new
stribild complera genvoya
truvada/atripla still hold market
right mean signific number
still need switch howev given time
solid taf switch data believ
least half market switch
car-t gilead acquisit kite provid
potenti renew long term revenu
main driver hiv franchis
hcv franchis car-t franchis
pipelin capit deploy repres
key driver
risk achiev price
unexpect competit hiv
rapid hcv eros
appreci consensu
failur car-t achiev signific
market penetr failur meaning
signific delay regulatori
progress jak inhibitor filgotinib
clinic success market penetr voxelotor previous drive
clinic success market penetr voxelotor previous drive
peak penetr voxelotor assum voxelotor demonstr
abil modifi lt marker scd pain sickl crise thrombot event
new standard care assum limit competit gene therapi
peak penetr voxelotor assum clinic success voxelotor
compar success gene therapi voxelotor gene therapi split
voxelotor fail case assum residu cash valu
market signific unmet medic
need voxelotor oral dose potenti
diseas modifi therapi posit well
compet market new therapi
decad market share suggest
us peak sale potenti
earli voxelotor data compel initi
data demonstr reduct sickl
cell improv red blood cell
marker hemoglobin reticulocyt ldh
believ data could translat
clinic outcom includ reduct
sickl crise pain thrombot event
market assumpt leav room
competit current model
peak penetr hbss leav room
gene therapi believ oral dose
could prefer gene therapi could offer
cur therapi could
prefer patient
regulatori progress potenti
commerci launch voxelotor
risk achiev price
regulatori setback failur
greater success competitor therapi
gene therapi
epidiolex ramp drive gw share
epidiolex ramp drive gw share
pt deriv dcf use discount rate
termin growth rate beyond valu
program cannabinoid base therapi rare neurolog
epidiolex exce expect drug ramp well label indic
dravet lenox-gastaut strong label use expect revenu
use gradual ramp expect revenu exceed
epidiolex ramp slower expect assum drug ramp well
label indic less steepli anticip off-label use minim
gw market leader medic
applic cannabis-rel intervent
sativex approv eu epidiolex
recent approv fda
transfer schedul
june food drug
cannabidiol cbd oral solut
treatment seizur two rare sever
form epilepsi lennox-gastaut syndrom
dravet syndrom believ epidiolex
would wide use treatment
refractori pediatr epilepsi on-label
off-label
sale ramp epidiolex primari
driver share valu
risk achiev price
payer impos signific restrict
physician hesit prescrib
gwph adr british base
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid tnbc muc
bull case assum achiev greater adopt ww peak risk
adjust sale assum commerci treatment line
mtnbc acceler adopt muc er cancer
base case assum launch mtnbc addit
revenu stream earlier line muc er larg enter
assign risk adjust use mtnbc ww risk adjust sale
bear case assum fail receiv approv indic
stock trade cash valu
equal-weight driven concern
around uncertainti approv timelin
requir follow
sidelin fda
continu believ efficaci
safeti data see signific
unmet need mtnbc believ approv
could see rapid adopt peak
believ obtain multipl
label expans increas asset total
address market studi front line
mtnbc muc er breast cancer could
remedi approv
phiii data random ascent
studi mtnbc treatment earlier line
data pivot phii studi trophi
muc hormon breast cancer
risk achiev price
management fail correct cmc-relat issu
competit landscap target
therapeut mtnbc increas
failur achiev signific label
expans earlier line therapi
licens fee revenu
research develop
chang fair market valu warrant liabil
net loss attribut nci
net incom non-gaap
equival
account receiv net allow doubt account
properti equip net
account payabl accru expens
liabil relat sale futur royalti current
convert senior note net unamort debt issuanc cost
liabil relat sale futur royalti non-curr
capit contribut excess par
non-control interest subsidiari
total liabil equiti
oper
adjust reconcil net loss net cash use oper activ
chang fair valu warrant liabil
depreci amort
amort defer revenu
amort bond premium
amort debt issuanc cost
amort defer rent
sale market secur
increas decreas allow doubt account
non-cash expens relat stock compens
non-cash decreas valu life insur polici
accru interest non-recours debt
chang oper asset liabil
account payabl accru expens
net cash use oper activ
purchas market secur
proce sales/matur market secur
purchas properti equip
net cash use invest activ
sale prefer stock net relat expens
proce issuanc convert senior note net
proce issuanc non-recours debt net
payment debt issuanc cost
proce public offer common stock/warr net expens
proce privat offer common stock
exercis stock option
tax withhold payment stock compens
net cash provid financ activ
effect chang exchang rate cash cash equival
chang
cash equival restrict cash begin year
cash equival restrict cash end year
jak backbon modest pipelin success key ew thesi
modest pipelin success key ew thesi
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum differ wacc indic
termin growth deriv npv assign probabl
factor drug/condit reflect clinic regulatori
risks/tim sum risk-adjust npv add cash excess
commerci out-performance jakafi greater baricitinib sale potenti success
across pipelin includ front-lin gvhd
increas penetr myelofibrosi polycythemia vera continu
drive jakafi revenu peak sale modest baricitinib royalti
pipelin success
jakafi underperform appear unlik reach compani peak
guidanc baricitinib launch poorli assum minim valu
pipelin beyond jakafi iclusig olumi royalti
jakafi provid stabl revenu backbon
revenu grow annual patent
expiri driven continu uptak
myelofibrosi polycythemia vera
pipelin continu matur
mix success see success gvhd
asset pipelin could mix
success thu wait greater clariti
key valuat driver commerci
execut approv drug well
perceiv clinic regulatori risk
data pivot gravita trial
itacitinib gvhd
risk achiev price
jakafi uptak less anticip
baricitinib fail obtain approv and/or
jakafi fail gvhd label
pt includ jakafi sale myelofibrosi mf polycythemia vera pv royalti
jakavi sale europ iclusig sale all/cml europ royalti baricitinib
sale rheumatoid arthriti atop dermat jak use graft-versus-host diseas
gvhd usag b-cell malign
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use company-wid discount rate
termin growth rate model forecast revenu expens
opportun beyond anticip exclus period product
product ip beyond expiri assign termin valu
breo anoro success drive risk reward
breo anoro success drive risk reward
pt deriv dcf assum discount rate
breo anoro captur signific share market bull case
assum breo anoro characterist qd dose breo lack
ic anoro drive major share copd asthma
prescript given sluggish launch drug comfort
physician approv laba/icss see scenario unlik
model peak ww sale breo anoro
trelegi
breo anoro sluggish launch case assum breo
anoro gain modest share copd/asthma prescript model peak ww
sale breo anoro trelegi
dcf valu equiti stream royalti less net-debt
breo anoro falter commerci bear case assum breo anoro
fail gain commerci traction model ww sale breo anoro
trelegi
underweight see limit
upsid valuat impli
potenti gsk consolid royalti
interest breo/anoro
launch breo anoro
sluggish far
breo qd dose potenti complianc
advantag howev top-line result
breo phiii trial suggest profil similar
patient switch approv laba/icss
compet least initi
laba/ class mean growth anoro
expect maba/tripl combo
cannib sale breo anoro
patient need come laba/
lama/laba take one drug
key driver model includ
royalti breo launch
anoro launch
risk achiev price
breo and/or anoro may sell better
compani may potenti
busi develop transact may
penetr durat ali therapi key valuat driver
penetr durat ali therapi key valuat driver
pt deriv dcf use discount rate
termin growth rate revenu driver model ali
market penetr us japan refractori frontlin
mainten treatment ntm
ali launch us japan achiev
penetr respect refractori ntm popul major
patient take form mainten treatment also forecast low
doubl digit penetr frontlin popul us japan peak sale
respect
ali launch us earli japan reach
penetr respect refractori ntm popul less
modest frontlin penetr us japan peak sale
ali achiev commerci
overweight insm given robust
data ali refractori induc ntm
patient derisk approv also provid
modest assumpt chronic dose
opportun note current data argu
investig label
geograph expans japan provid
addit lever see substanti
foreign sale larger ntm popul
prioriti review fda advisori
prepar japan file pmda
follow-up data long-term extens
convert studi full data
risk achiev price
failur reach market restrict
label target small portion
poor long term durabl driven
dropout safeti signal less differenti
standard treatment
delay life cycl manag studi
need obtain robust mainten
spinraza grow focu shift tegsedi
spinraza grow focu shift tegsedi
pt deriv dcf use discount rate
termin growth rate beyond valu ioni advanc
driven revenu upsid across lead pipelin drug assum rapid
penetr spinraza thrombocytopenia concern physician
patient allow tegsedi success hit market appli modest pipelin
valu drug includ ionis-fxi
ionis-htt
spinraza tegsedi drive valu assum rapid spinraza penetr upon
launch tegsedi sale grow thrombocytopenia limit launch appli modest
pipelin valu drug includ ionis-fxi
apo -l ionis-htt
ioni unabl launch addit product base case scenario assum
spinraza sale fall short expect commerci challeng
emerg respect platform pipelin drug
long haul view antisens
promis drug develop
platform equal-weight ioni
believ safeti toler concern
like remain overhang share
tegsedi launch underway expect
thrombocytopenia concern weekli
blood monitor could put damper
spiranza blockbust treatment
type sma tegsedi like increas
focu drug launch
thrombocytopenia particular -- could
challeng tegsedi
spinraza continu grow spinal
muscular atrophi sma increas
emphasi type patient investor remain
wari compet gene therapi novarti
share would driven compani
extens develop pipelin
numer near- medium- long-term
risk achiev price
news flow regard either success
failur ioni pipelin could lead
swing share valu
data ioni pipelin alter
efficaci and/or safeti profil
clinic data competit program
alter dynam market ioni
current pursu
use wacc termin growth rate
linzess becom domin player ib cic market linzess
prefer treatment ib cic domin prescript
product take greater share over-the-counter therapi push past
linzess remain steadi grower linzess gradual grow share ib cic
market beat brand player make headway
expens over-the-counter therapi net sale push past
linzess slow ibs-c cic market slow tough competit take share
equal-weight ironwood
expect linzess growth like stabil
multipl quarter
ration post expect spin
cyclerion push ironwood
toward profit
key revenu driver model
risk achiev price
enabl upside/downsid versu
one compani pipelin drug could
achiev superior data lead us
increas expect regard
ration exceeds/fal short
expect lead upside/downsid
data ucd program drive risk/reward
data ucd program drive risk/reward
pt deriv dcf use discount
rate termin growth rate revenu driver model
ucd
greater diagnosi rate larger set address patient ucd
vs base case ucd program gener peak risk-
adjust global sale respect assum
kaleido program approv overt minim patient appli
risk adjust ucd program respect
ucd program approv therapeut receiv signific
patient uptak ucd program gener peak risk-adjust
global sale respect uptak drive
bulk revenu due greater share higher price compar eu
assum kaleido program approv overt
popul appli risk adjust ucd
kaleido pipelin fail ucd program fail kaleido unabl
commerci mmt therapi assum share trade cash
value-per-share case
overweight kaleido thesi
base success commerci
mmt product treatment urea
cycl disord ucd hepat
kaleido take differenti approach
toward leverag gut microbiom
develop synthet analyt
capabl enabl kaleido gener
product candid rapidli kaleido
test mmt candid human non-ind
studi mmt complex carbohydr
molecul relat gra
gener recogn compound
allow kaleido progress directli
phii studi ind set-up
may facilit speed market
abil progress product candid
strong proof-of-concept human
non-ind studi healthi
toler profil abil reduc
achiev statist signific base
earli yet encourag result
believ could lead posit result
clinic studi patient could progress
becom viabl therapeut ucd
ucd kaleido second lead
program addit program
also plan infect caus multi-
kidney diseas cardiovascular diseas
program current earli
believ could becom futur pipelin
driver data lead ucd
program prove posit
data non-ind studi
data non-ind studi
ucd patient
data phii studi ucd
ind
risk achiev price
poor efficaci data surpris neg
safeti signal non-ind studi
poor phii data ucd patient
make investor question viabil
platform
neg data microbiom
compani weigh share
regulatori chang compromis
kaleido abil conduct non-ind studi
human could lengthen time
market push product revenu
futur
durabl data wet age-rel macular degener drive risk/reward
durabl data wet age-rel macular degener
pt deriv dcf use discount
rate revenu driver model kodiak lead anti-vegf
candid retin diseas
commerci multipl retin diseas strong uptak
commerci wet diabet eye diseas peak
penetr probabl success po total risk-adjust
revenu grow
commerci limit set retin diseas modest
uptak commerci wet peak
penetr probabl success po total risk-adjust revenu
grow peak
fail kodiak unabl develop trade cash
overweight thesi base
success commerci
sever compani commerci
anti-vegf therapi treatment
retin diseas burden monthli
bimonthli treatment reduc long
design extend therapeut
durabl compar current therapi
preclin data well-establish rabbit
model demonstr extend durabl
clean safeti profil
initi clinic data direct phib
phii interim analysi demonstr
demonstr efficaci durabl
wet diabet eye diseas
multipl studi begin
risk achiev price
investor question valu
increas toxic advanc patient
posit data competitor could weigh
market share especi
competitor data arriv prior pivot trial
sale
research develop
gener administr
cash equival
prepaid expens current asset
properti equip net
accru current liabil
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
non-cash interest expens amort debt discount issuanc cost
chang fair valu redeem convert prefer stock warrant liabil
chang fair valu deriv instrument
extinguish debt
chang oper asset liabil
prepaid expens current asset
net cash use oper activ
purchas properti equip
net cash use invest activ
proce issuanc convert prefer stock net issuanc cost
princip payment capit leas
proce issuanc common stock
princip payment tenant improv allow payabl
payment repurchas earli exercis stock option
net cash provid financ activ
net increas decreas cash cash equival restrict cash
cash equival restrict cash begin period
cash equival restrict cash end period
margituximab posit updat proprietari dart bispecif platform
posit updat proprietari dart bispecif platform
advanc therapeut program
strong uptak margituximab enoblituzumab bull scenario assum
sale treatment breast gastric cancer scenario also
assum enoblituzumab achiev success trial launch
treatment multipl solid tumor includ pipelin valu potenti
margetuximab peak margetuximab achiev modest success
studi find place nich therapi refractori breast cancer patient
includ pipelin valu potenti dart platform
failur commerci proprietari partner program macrogen
gener product relat revenu
equal-weight macrogen
macrogen one pure play
biotech broad bispecif antibodi
platform though believ platform
substanti potenti would like
see ampl data appli higher
like efficaci treatment cancer
manufactur packag dart
broadli applic implement
beyond oncolog effort underway
treat autoimmun infecti
diseas dart could effect safeti
toler issu could present
program offer support
valuat though modest
expect margetuxemab direct
valid target could yield
sale provid downsid support
respect target enoblituzumab
think could offer greatest util
combin checkpoint inhibitor
would like see data
increas expect
clinic data dart bispecif
antibodi beyond
updat phase compound
margetuximab bolster downsid
support valuat
clinic updat includ
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data
therapeut program
poor data bispecif program
cast doubt bispecif overal
deriv pt dcf base forecast
mrna base product candid use
discount rate termin growth rate
strong share pipelin program bull case valu
program base case well oncolog relaxin heart
failur fabri program risk adjust vari product
launch begin gener sale
flow flow
success pipelin program base case valu rsv
cmv hmpv pcv kra cancer vaccin program vegf-a
rare diseas program mma pa pku risk adjust vari
product launch begin gener sale
flow
flow
product candid face technology/clinical/regulatori failur
therefor gener revenu share trade cash value-per-share
overweight moderna compani
taken industri approach
develop mrna base therapeut
rapidli gener broad pipelin
program candid enter
mrna drug develop platform
diversifi scalabl compar
competitor mrna space
valid broad partnership
merck astrazeneca
signal gener preclin
earli clinic studi date indic
mrna therapeut activ
across wide varieti modal
indic rang prophylact
cancer vaccin rare diseas believ
mani program repres
abl screen product
candid rapidli due digit
manufactur capabl compani
plan progress five new product
candid clinic everi year
coupl initi proof-of-concept data
area enzym replac
disord would valid key area
approach allow signific
increas pipelin probabl success
addit earli clinic stage data
intratumor i/o local regen
therapeut modal
expect
nomin addit drug candid
risk achiev price
initi data platform
beli investor expect caus
investor write-off subsequ readout
delay abil gener
stronger expect competitor data
sale
research develop
gener administr
oper expens
cash equival
prepaid expens current asset
properti equip net
accumul comprehens loss
total liabil redeem convert prefer stock stockhold deficit equiti
adjust reconcil net loss net cash use oper activ
amort invest premium discount
loss dispos properti equip
chang oper asset liabil
prepaid expens current asset
net cash use oper activ
purchas market secur
proce matur market secur
proce sale market secur
purchas properti equip
increas restrict cash
net cash use invest activ
proce issuanc redeem convert prefer stock net issuanc cost
distribut prefer common unit holder
proce issuanc stock exercis stock
net cash provid financ activ
net increas decreas cash cash equival restrict cash
cash equival restrict cash begin period
cash equival restrict cash end
mavacamten drive risk/reward
mavacamten drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth rate assum peak us
market share ohcm nhcm dcm
translat peak us sale
respect adjust use probabl success po
ohcm po nhcm po dcm
higher po pipelin product assum higher po dcm
ohcm nhcm follow posit data readout
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
precis medicin platform fail unabl advanc product
candid trade cash value-per-share
overweight myokardia
well-defin subgroup unmet medic
need potenti grow beyond
promis phase data
gener lead asset mavacamten
show reduct left ventricular outflow
tract lvot gradient week
provid opportun upsid
enter clinic advanc
nhcm
phase data dcm
ohcm
risk achiev price
poor efficaci concern safeti data
maverick-hcm lower
probabl success nhcm
concern safeti data
phase prevent advanc
studi
pt deriv dcf use discount rate
termin growth rate beyond valu nabriva antibiot
lefamulin achiev strong ramp inpati outpati set drug
achiev peak sale contepo exce expect exceed
sale expect gener might enter market
lefamulin achiev modest share iv use lead oral use discharg set
risk adjust lefamulin sale expect reach
contepo approach risk adjust sale
antibiot unabl get approv stock valu cash
lefamulin novel mechan action
provid need option cabp nabriva
lefamulin first-in-class system
pleuromutilin develop oral iv
use treat community-acquir bacteri
pneumonia cabp lefamulin cabp
target spectrum activ novel
mechan action resist seen
date provid import altern
option treatment cabp
expect gradual commerci adopt
lefamulin sale driven use
inpati set nabriva initi
target inpati set sale
rep target highest
prescrib hospit repres
would key highli competit
lefamulin sale
acquisit zavant add second first-
in-class antibiot portfolio contepo
first-in-class epoxid could
potenti approv cuti although
opportun somewhat modest project
peak risk adjust sale
key valu driver perceiv clinic
regulatori risk lefamulin
risk achiev price
process could challeng
lefamulin and/or contepo sale fail
potenti addit dilut financ
pt base dcf base case forecast
metastat melanoma nsclc bladder cancer use
discount rate termin growth cash flow
higher probabl success greater market share assum
probabl success melanoma nsclc bladder cancer also
assum higher market share versu base assum peak sale
risk-adjust success assum probabl success
across melanoma nsclc bladder cancer assum peak sale
fail clinic develop assum cash valu
overweight neon therapeut
believ neoantigen relev vaccin
target believ improv
efficaci tradit immun target
agent
initi data support immun
respons impact vaccin week
follow-up import determin
manag industri
platform informat need produc
person vaccin
data phi studi
expect juli
risk achiev price
failur initi clinic
neoantigen approach
mrna gener superior data peptid
neoantigen screen technolog still
novel neon platform may sub-optimal
compar other may select
wrong neoantigen could lead poor
pt deriv dcf use discount
rate assum peak us market share td also model
peak us market share opicapon parkinson translat
ingrezza sale growth beat expect assum peak market share
vy-aadc abl reach market late
unadjust us ingrezza sale td base case assumpt
detail price target methodolog
slower growth td sale bear case assum lower peak us market
share ingrezza td translat peak sale
addit assum vy-aadc unsuccess reach market
overweight thesi driven ingrezza
even though question
whether growth slow think
possibl achiev peak sale despit
continu declin growth
partnership voyag offer
exposur larg market earlier
end-of-phas meet
potenti approv orilissa uterin
risk achiev price
ingrezza sale growth td may continu
deceler
vy-aadc pivot studi enrol
expect safeti concern aris
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share
adjust use probabl success po
higher po assum higher po peak share follow posit
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
immunotherapi platform fail unabl advanc product
candid trade cash value-per-share
overweight nextcur
defin subgroup unmet medic need
potenti expand beyond
sinc express
overlap tumor tumor
respond therapi
initi cut data phase show
promis earli sign activ
addit program pipelin
candid find-io platform
provid opportun upsid enter
clinic advanc develop
phase proof-of-mechan data
phase proof-of-concept data
ind solid tumor
phase proof-of-mechan data
phase proof-of-concept data
risk achiev price
poor efficaci and/or safeti data lead
product candid lower po
lack advanc early-stag pipelin
ew base key unknown
risk associ launch andexxa
clariti launch metric
need physician support
factor xa antidot consider bleed
signific potenti devast
complic anticoagul
revenu driver model
launch andexxa us eu row
risk achiev price
andexxa could launch poorli
obtain signific uptak physician
andexxa could face execut
andexxa becom standard care bleed model detail follow
andexxa launch us eu andexxa peak ww
sale
andexxa major driver valuat model detail follow
andexxa launch us eu andexxa peak ww
sale
andexxa achiev base case peak sale assum andexxa
slow ramp modest us penetr andexxa ww sale peak
program osteoporosi drive risk/reward
program osteoporosi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model tymlo osteoporosi risk adjust sale
elacestr neg metastat breast cancer
market leadership growth osteoporosi limit pressur forteo
gener risk-adjust elacestr bull case assum tymlo pen
patch achiev acceler switch forteo user minim impact
gener ww peak sale
pen patch elacestr respect
competit uptak tymlo commerci long term market
transfer patch probabl success po elacestr base
case assum tymlo obtain competit formulari posit
also commerci patch assum modest
pressur forteo gener assum gener price line
tymlo ww sale tymlo pen patch elacestr
respect
loss treatment popul forteo gener poor commerci
patch elacestr fail bear case assum tymlo pen increasingli
pressur entri multipl forteo gener patch fail
substanti grow anabol market ww peak sale
pen patch respect
overweight radiu compani
osteoporosi platform gener solid
data commerci pen earli sign
encourag launch lead us believ
tymlo captur sizeabl portion
anabol market formulari win
market transfer tymlo pen
tymlo patch establish sticki
patient popul face forteo
gener see tymlo brand
abl achiev share peak
addit program breast cancer
contribut signific upsid valuat
believ demonstr
encourag data current standard
initi pivot studi patch
time launch price potenti
risk achiev price
disappoint launch trajectori tymlo
track prescript data formulari
elacestr fail demonstr
improv standard care
failur defend market share
gener includ inabl bring patch
market
eylea dupix drive risk-reward
eylea dupix drive risk-reward
better dupix penetr atop dermat asthma assum
us eylea row eylea sarilumab us
sale us dupilumab sale also
assum injunct place sale praluent
sarilumab me-too compar actemra strong dupix penetr
asthma atop dermat assum us eylea
row eylea us sarilumab sale
us dupilumab sale assum probabl
injunct sale praluent
praluent remain market sarilumab still me-too
modest dupix launch eylea face greater branded/biosimilar
competit assum us eylea row eylea
contribut praluent given complet injunct
modest row praluent sale sarilumab
us sale dupilumab sale
equal-weight regeneron
investor heavili scrutin dupix
prescript data sinc launch atop
dermat ad april believ
consensu still factor substanti sale
dupix ad well asthma see
risk/reward skew slightli
posit given steadi launch ad
recent approv asthma emerg
pipelin i/o see littl room near-
dupix initi launch trajectori
dupix encourag ad see
dupix durabl asset asthma
current project dupix sale
across atop dermat
praluent factor watch
develop new trial proceed
sanofi/regeneron
 praluent inflect come quarter
kevzara sarilumab see kevzara
me-too forecast sale
main driver dupix dupilumab
eylea emerg i/o pipelin
risk achiev price
unexpect flatten dupix
dupilumab launch trajectori
disappoint uptak asthma
competit success wamd space
limit uptak i/o asset
contract research revenu
collabor manufactur
regeneron share profit/loss zaltrap commerci activ
reimburs regeneron research develop expens
profit/loss connect commerci antibodi
sanofi reimburs regeneron sell expens
up-front payment sanofi acquisit right relat two antibodi
off-set reimburs cost
reimburs regeneron research develop expens
profit/loss connect commerci
reimburs regeneron research develop expens
cost-shar regeneron eylea develop expens
regeneron net profit connect eylea exu commerci activ
reimburs regeneron research develop expens
contract research revenu
cash equival
prepaid expens current asset
properti plant equip net
account payabl accru expens
defer revenu sanofi
defer revenu
defer revenu sanofi
defer revenu
accumul comprehens income/loss
total liabil equiti
depreci amort
loss extingush debt
non-cash charg expens net
chang oper asset liabil
net cash produc use oper activ
purchas available-for-sal secur
matur sale available-for-sal secur
increas restrict cash market secur
net cash provid use invest activ
proce facil leas oblig
payment facil capit leas oblig
proce issuanc convert note
proce issuanc warrant
repurchas common stock
proce issuanc common stock
payment stock tender employe tax oblig
excess tax benefit stock-bas compens
net cash provid financ activ
chang cash
begin period
end period
success use
success use partner proprietari program drive
technolog partner proprietari program drive
pt deriv dcf use discount rate
termin growth rate valu proprietari partner
commerci proprietari partner program model
strong uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi sale gener peak
royalti revenu
commerci proprietari partner program model
modest uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi revenu gener peak
royalti revenu
failur commerci proprietari partner program
receiv royalti avexi gener product relat
revenu bear case consist cash value-per-share well valu
royalti novartis/avexi sma program eu
overweight regenxbio believ
compani technolog platform
alreadi broadli licens across
potenti transform method
safe effect deliv gene
known target clear endpoint
reduct hofh reduct gag
accumul mp mp ii
arrang de-risk platform
help reduc binari risk face
success licens program use
vector deliveri method
reduc technic risk face proprietari
recent posit gene therapi data
help de-risk broader gene therapi
data/upd wet
hofh program
advanc
program mp mp ii respect
updat avexi sma program
technolog license
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data gene
therapi program develop
either technolog license gene
therapi compani use vector outsid
platform
cost expens
sale
research develop includ amount relat parti
gener administr includ amount relat parti
accret dividend convert prefer stock prefer unit
net gain extinguish prefer stock
non- adjust
research develop
gener administr
st invest
cash equival
properti equip net
due relat parti servic agreement
convert prefer stock prefer unit
accumul comprehens loss
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
non-cash consider receiv licens grant
imput interest relat parti promissori note
net amort premium accret discount market debt secur
depreci amort
chang oper asset liabil
due relat parti servic agreement
net cash use oper activ
purchas sale market secur
purchas properti plant equip
net cash use invest activ
proce issuanc common stock
proce relat parti promissori note
net cash proce issuanc prefer stock
proce exercis stock option
proceed issuanc seri convert prefer stock
proce issuanc seri convert prefer stock
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
pt deriv dcf use discount rate
termin growth rate beyond valu rhythm program
orphan genet disord obes
setmelanotid approv launch pomc null lepr defici
setmelanotid data bardet-biedl syndrom bb alstrm
suggest drug could exceed expect indic rais
confid combin phiii trial
setmelanotid like reach market pomc null lepr
defici data bardet-biedl syndrom largest valu driver
model appear promis await data move risk
adjust higher incorpor alstrm risk
adjust estim peak sale setmelanotid
setmelanotid fail reach market rhythm trade cash
compel efficaci setmelanotid
two ultra-orphan diseas may result
setmelanotid underway data
expect studi
success would enabl regulatori
bardet-biedl signific
opportun rhythm pursu bardet-biedl
syndrom alstrm syndrom
addit indic rhythm present
data indic suggest
setmelanotid could offer benefit
patient phiii trial examin
indic set begin later year
increas rate diagnosi upon launch
key challeng import lever
setmelanotid commerci success
view increas test diagnosi
rate genet disord obes
patient target ideal candid
setmelanotid therapi current
undiagnos anticip
avail therapeut target
increas test diagnosi rate
believ rhythm would need invest
meaning captur patient
realiz potenti market opportun
key valuat driver perceiv clinic
regulatori risk setmelanotid
syndrom pomc heterozyg obes
risk achiev price
fail clinic trial setmelanotid
rhythm unabl enrol pivot trial
orphan indic
potenti dilut financ
initi rct data diseas ind file drive risk/reward
initi rct data diseas ind file drive risk/reward
pt deriv dcf use discount
rate termin valu onward base
termin growth rate valuat assign credit rubiu rare
diseas oncolog platform
commerci rare diseas oncolog immunolog strong
uptak commerci rare diseas pku gout
homocystinuria oncolog nsclc immunolog pemphigu vulgari
probabl success po pku gout
homocystinuria nsclc pemphigu vulgari total risk-adjust
revenu grow
primari revenu contributor peak pku gout
commerci rare diseas oncolog modest uptak
commerci rare diseas pku gout homocystinuria
nsclc within oncolog pku assign po gout homocystinuria
valu po nsclc assign po pku
commerci product candid launch
total risk-adjust revenu grow
peak primari revenu contributor peak
pku gout
red platform fail rubiu unabl develop rct product candid
trade cash value-per-share
overweight thesi base
broad safe potenti applic
rubiu red platform could gener
diseas oncolog immunolog
pose white blood cell therapi like car-
includ broader applic off-the-
shelf approach improv safeti
rapid scalabl manufactur
preclin data encourag
date particularli rare diseas
platform ind applic lead
product candid
phenylketonuria pku approv fda
key risk across rubiu rare
diseas program deliveri risk
believ posit initi data
patient would address investor concern
significantli derisk rare diseas
program includ refractori gout
initi phi/ii studi
interim data patient
subsequ ind file futur rct
product candid
poor safeti and/or efficaci data rtx-
would like caus investor question
rubiu abil gener effect
investor may subsequ question
valu red platform assign limit
valu rare diseas oncolog
accret seri redeem convert prefer stock redempt valu
oper expens
non- adjust
research develop
gener administr
short circul time would
impair commerci prospect
platform could lead limit efficaci
posit data competitor either
platform compani
weigh rubiu share especi
competitor data arriv prior meaning
dataset rubiu
sale
research develop
gener administr
cash equival
prepaid expens current asset
properti equip net
accru expens current liabil
current portion long-term debt
long-term debt net discount current portion
liabil earli exercis stock option
accumul comprehens loss
total liabil stockhold equiti
proce issuanc redeem convert convert prefer stock net issuanc cost
proce issuanc common stock upon exercis stock option
proce sale restrict common stock
payment debt issuanc cost
proce borrow loan secur agreement
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
adjust reconcil net loss net cash use oper activ
depreci amort
issuanc common stock technolog licens
chang fair valu prefer stock warrant liabil
accret discount market secur
loss dispos properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
purchas properti equip
purchas market secur
net cash use invest activ
brexanolon launch primari valuat
brexanolon launch primari valuat
brexanolon approv asset
global peak sale potenti
clear unmet need form basi
valuat clear upsid
derisk data mdd
potenti much broader profil
insomnia parkinson diseas addit
indic multi-billon dollar
pipelin broad continu offer
new drug extens effort target
gaba nmda
brexanolon launch steep trajectori provid
bulk valuat strong launch mdd bipolar
insomnia
brexanolon key near-term driver
launch howev form
bulk valuat
brexanolon launch provid bulk valuat
launch mdd bipoloar insomnia
approv mdd bipolar insomnia
launch modest
neg safeti efficaci data
therapeut program
unexpect delay clinic
potenti intellectu properti
challeng could impact futur revenu
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat gene therapi
base case scenario assum continu strength exondi well
approv golodirsen camisersen risk-adjust dmd
gene therapi total revenu
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd gene therapi
product gene therapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd gene therapi
program includ risk relat
manufactur on-going regulatori
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
equal-weight syndax
develop class hdac entinostat
near-term compani stock
leverag outcom phiii
trial hr breast cancer although
menin-llr program intrigu
confid entinostat/checkpoint
inhibitor combin wane somewhat
although could eventu path
forward inflam tumor nsclc
melanoma
stock valuat highli link
success phiii trial
risk achiev price
neg safeti efficaci data
therapeut program
unexpect challeng checkpoint
inhibitor i/o therapi gener
could dampen syndax opportun
potenti intellectu properti
challeng could impact futur revenu
assum entinostat achiev rapid uptak hr bc uptak
combin i/o therapi nsclc melanoma also assum
combin hormon therapi hr breast cancer exce base case
expect incorpor project risk adjust i/o combin
sale hr her- sale
assum bulk valu come entinostat combin i/o
therapi howev valuat base lower sale project
risk adjust i/o assum modest hr her- breast cancer sale
project risk adjust
assum entinostat fail achiev suffici clinic result either hr
her- breast cancer i/o combin studi
crysvita drive risk/reward
crysvita
pt deriv dcf use discount
rate model peak risk-adjust revenu addit
peak ww sale mepsevii crysvita
model peak unadjust ww sale
adjust
use probabl success po
posit data readout better-than-expect launch assum higher
po po follow subsequ
confirm posit data cohort cohort respect
support advanc program phase addit assum
better-than-expect launch lead greater peak market share
crysvita mepsevii
strong crysvita launch base case assumpt describ price
target methodolog
pipelin product fail bear case assum fail
approv call question mepsevii crysvita face
slower adopt us
overweight rate base
belief street undervalu
crysvita launch remain strong
potenti upsid greater adopt
adult famili
data promis
confid program
like ultragenyx third
compani continu deepen
diversifi pipelin new gene therapi
mrna candid
phase cohort data over-the-counter
phase cohort data
clariti ema potenti
file lc-faod phase data
risk achiev price
crysvita mepsevii may face
commercial/reimburs challeng
achiev suffici patient adopt
data subsequ indic
pipelin candid may succeed
even data posit fda may
probabl success anti-ag market well osteoarthr knee
probabl success anti-ag market well osteoarthr knee
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model osteoarthr oa addit
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli remain bull case
program fail valu compani cash
manag pioneer novel
biolog senesc cell
opportun deliv step-funct chang
treatment chronic diseas
preclin model support
impact sasp factor senesc
suggest benefit
remov senesc cell
oa offer proof-of-concept model
clear biomark clinic endpoint
follow-up long-term chronic data
addit ind file follow-up
product includ eye
risk achiev price
biolog approach
novel initi program fail falter
investor like heavili discount
competit space
privat
initi oa program may right
target test senesc cell snc
follow-up period dose period
medicin may long enough
kinet remov snc see
therapeut respons known
fair valu contig consider
equival
prepaid expens current asset
properti equip net
accru current liabil
defer rent net current portion
parti promissori note purchas comon stock
total liabil equiti
adjust reconcil net loss net cash use oper activ
depreci amort
loss sale equip
amort premium discount market secur
loss extinguish promissori note
common stock grant third parti
accret tenant improv allow
chang oper asset liabil
prepain expens current asset
accru liabil current liabil
defer rent net current portion
net cash use oper activ
purchas market secur
matur market secur
purchas cost method invest
purchas properti equip
net cash use incest activ
proce fom issuanc convert promissori note payabl
proce issuanc convert prefr stock net
proce issuanc common stock upon exercis stock option net
payment made capit leas oblig
net cash provid financ activ
chang
begin year
 restrict end year
market secur end year
oper
base case forecast deriv explicit forecast
bcma actr product discount
better efficaci safeti signal solid tumor model peak sale
liquid tumor bcma myeloma posit initi data
allow us valu solid tumor opportun implicitli
higher termin valu
activ product use refractori
patient take share current approv car-t base
cleaner safeti profil model peak sale includ
base valu program fail
ow unum base view
technolog could provid
robust therapeut window compar
especi solid tumor
believ manag outlin
reason strategi deal toxic
encount initi phi studi
initi solid tumor data
addit data rituximab
sea-bcma
initi dose escal data
trastuzumab solid tumor attck-
updat data rituximab
nhl studi
dose escal data sea-
bcma multipl myeloma attck-
risk achiev price
safeti issu compromis actr
lack clean safeti efficaci
lack differenti
activ
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
ww penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
het/min homozygot addit tripl data commerci
success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr orkambi
homozyg cf patient eventu switch captur
homozyg het/min market tripl combo risk-adjust peak ww sale
tripl combin therapi
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient peak ww sale
kalydeco monotherapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi believ manag
potenti deliv ep overtim
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco uptak in-
develop therapi tez/iva triplet
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data clinic candid tripl
combin fail meet expect
data competit exce
equal-weight rate base limit
clinic catalyst
major valuat driven
vy-aadc parkinson
vy-aadc phase data
vy-aadc phase data
risk achiev price
enrol faster expect addit vy-
aadc data increas investor confid
program expect
earli stage candid advanc
clinic vy-aadc pivot studi
enrol expect safeti concern aris
longer term data reflect strong
durabl respons
vy-aadc parkinson drive risk/reward
vy-aadc parkinson drive risk/reward
pt deriv dcf use discount
rate model unadjust ww vy-aadc revenu
voyag receiv profit share us low-teen
royalti eu sale risk-adjust use po
huntington model peak unadjust ww sale
adjust use po
optimist view vy-aadc scenario assum po
follow strong long-term data greater market share vy-aadc us
eu
vy-aadc us launch base case assumpt describ
price target methodolog
gene therapi platform fail bear case assum voyag unabl
advanc product candid trade cash value-per-share
dasiglucagon glepaglutid driver
dasiglucagon glepaglutid driver
pt deriv dcf use discount rate
glepaglutid dasiglucagon demonstr superior profil product
differenti sb hypoglycemia respect lead acceler
uptak versu current standard care
dasiglucagon glepaglutid competit pipelin asset
approv view competit standard care
late state pipelin falter dasiglucagon glepaglutid fail reach
strong pipelin support ow rate
view zealand strong pipelin
led two therapi glepaglutid
dasiglucagon improv version
standard care drug
dasiglucagon could better offer
dasiglucagon rescu medic
sever hypoglycemia repres
conveni offer current market
glucagon like drive strong uptak
therapi approv potenti futur use
artifici pancrea system orphan
repres upsid estim
glepaglutid next-gen
could improv profil teduglutid
earlier featur short half
life requir complex multi-step
reconstitut process prior administr
glepaglutid enhanc stabil
extend half life allow drug
glepaglutid dasiglucagon success
risk achiev price
fail clinic trial pipelin candid
dasiglucagon glepaglutid
potenti need rais dilut equiti
